No Data
No Data
Shanghai Shyndec Pharmaceutical (600420.SH) subsidiary pharmaceutical passed the consistency evaluation of generic drugs.
Shanghai Shyndec Pharmaceutical Co., Ltd., a subsidiary of the listed company Shyndec Pharmaceutical, recently received the Supplemental Approval Notice for Drug Application issued by the National Medical Products Administration approving the consistency evaluation of the generic cephalosporin sodium injection. Cefoperazone sodium for injection is a third-generation cephalosporin antibiotic, suitable for lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, and bone infections caused by sensitive bacteria.
Shanghai Shyndec Pharmaceutical (SHSE:600420) Investors Are up 8.3% in the Past Week, but Earnings Have Declined Over the Last Five Years
Shanghai Shyndec Pharmaceutical's Chest Pain Drug Passes China's Drug Evaluations
Shanghai Shyndec Pharmaceutical (stock code 600420.SH): Its subsidiary pharmaceutical has passed the consistency evaluation of generic drugs.
On July 30th, Gelunhui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd. (referred to as Sinopharm Industrial), has received the "Drug Supplementary Application Approval Notice" issued by the State Drug Administration for the approval of nitrendipine sustained-release tablets (I) through the consistency evaluation of generic drug quality and efficacy. Nitrendipine is a dihydropyridine calcium antagonist developed by Germany's Bayer, mainly used to treat chronic stable angina (effort angina), vasospastic angina (Prinzmetal's angina, variant angina) and primary hypertension.
Shanghai Shyndec Pharmaceutical (600420.SH): NMN is a product of Dali Pharmaceuticals Germany GmbH.
On July 23, Gelunhui reported that Shanghai Shyndec Pharmaceutical (600420.SH) stated on the investor interactive platform that NMN is a product of the company's wholly-owned subsidiary, Dali Medicine Germany GmbH, which is mainly sold through cross-border e-commerce, and currently has a small sales scale. The company does not currently have an integrated production layout for this product.
Shanghai Shyndec Pharmaceutical (600420.SH): Production of 0.4679 million boxes of injectable Remifentanil hydrochloride in 2023.
On July 23rd, Gelunhui reported that Shanghai Shyndec Pharmaceutical (600420.SH) stated on the investor communication platform that it will produce 0.4679 million boxes of injection-grade Remifentanil hydrochloride in 2023, an increase of 20.75% from the same period last year. The company will actively ramp up production according to market demand. Furthermore, the manufacturing enterprise for this product, China National Pharmaceutical Group Co., Ltd. Industrial Co., Ltd., plans to build a new formulatory workshop project that has received planning permission and will further increase production capacity after completion in 2023.
No Data